It has been found that low concentrations of atropine have a role in myopia prevention and control. Atropine eye drops were originally used in ophthalmology as a pupil-dilating drug, but in recent years there have been studies surfacing that atropine can act as a blocker of the M1 and M4 receptors that regulate the growth of the eye axis. The essence of myopia progression is the growth of the eye axis. There are a large number of M1 and M4 receptors distributed in the choroid of the eye, and atropine can achieve the effect of controlling the growth of myopia by blocking these receptors. However, in the actual clinical application, it was found that the myopia control effect was positively correlated with the concentration of atropine, but the side effects of the drug were also positively correlated with the concentration of atropine, and the higher the concentration of atropine, the more likely to cause rebound after stopping the drug. Finally, after comparing different concentrations of atropine eye drops, it was determined that a low concentration of 0.01% atropine eye drops could provide good myopia control with fewer side effects and less rebound after stopping the drug. It is recommended that children with rapid increase in myopia should consult a doctor for evaluation of their condition and treatment under the doctor’s guidance.